ScienceFDA approves Tudriqev for unresectable advanced melanoma that progressed after PD-1 immunotherapy
Nature Biotechnology reports the approval of Replimune's Tudriqev, an oncolytic immunotherapy.
TLDR
Nature Biotechnology reports that the FDA has approved Replimune's Tudriqev for patients with unresectable advanced melanoma—melanoma that cannot be removed surgically—whose disease has progressed after PD-1 immunotherapy.
FDA approves Tudriqev for unresectable advanced melanoma that progressed after PD-1 immunotherapy
Nature Biotechnology reports the approval of Replimune's Tudriqev, an oncolytic immunotherapy.
TLDR
Nature Biotechnology reports that the FDA has approved Replimune's Tudriqev for patients with unresectable advanced melanoma—melanoma that cannot be removed surgically—whose disease has progressed after PD-1 immunotherapy.